ResultsIQ

ResultsIQ › Latest results › Jupiter Life Line Hospitals Limited

Jupiter Life Line Hospitals Limited Q1 FY26 earnings call summary

NSE: JLHL · BSE: 543980

Earnings call of 4 Aug 2025, summarised by AI from the filing.

Jupiter Life Line Hospitals Q1 FY26 total income ₹347.6 cr, up 20.5%, with EBITDA margins likely preserved but PAT margins lower this year.

Key takeaways

  1. Guidance EBITDA margins likely preserved for the full year, but PAT margins lower as the gap between PAT and EBITDA widens.
  2. Dombivli capex Around ₹200 cr spent so far and around ₹200 cr more to be incurred in the next few months till the Dombivli hospital starts.
  3. Volume growth Patient volume up 11.7% to 2.6-odd lakhs, led largely by Pune and Indore; absolute occupancy up about 5%.
  4. Margin risk Dombivli should have negative EBITDA in its first year, causing some consolidated margin compression next year.

Original filing on BSE

Jupiter Life Line Hospitals Limited Q1 FY27 results

As filed: Revenue ₹411 cr (+18% year on year), EBITDA ₹79.3 cr (+2% year on year), PAT ₹37.5 cr (−15% year on year), EBITDA margin 19.3% (−313 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹388 cr (+19% year on year), EBITDA ₹89.2 cr (+13% year on year), PAT ₹48.8 cr (+8% year on year), EBITDA margin 23.0% (−117 bps). Score 51 of 100, In line with trend. Revenue and profit growth were in line with the company's own trend; EBITDA growth was well below it. EBITDA margin fell 117 bps year on year. Revenue rose ₹60.8 cr on a year ago, more than the ₹37.0 cr it added the year before. Share price after the results: −0.8% in 28 days (Nifty 500: +0.3%).
  • Q3 FY26: Revenue ₹365 cr (+14% year on year), EBITDA ₹83.4 cr (+10% year on year), PAT ₹42.5 cr (−6% year on year), EBITDA margin 22.8% (−84 bps). Score 32 of 100, Below trend. Revenue, EBITDA and profit before exceptional items growth were well below the company's own trend. EBITDA margin fell 84 bps year on year. Revenue fell 7% from last quarter. Revenue rose ₹44.4 cr on a year ago, against ₹48.0 cr the year before. Share price after the results: −3.5% in 28 days (Nifty 500: +0.4%).
  • Q2 FY26: Revenue ₹394 cr (+22% year on year), EBITDA ₹92.0 cr (+23% year on year), PAT ₹57.0 cr (+10% year on year), EBITDA margin 23.4% (+13 bps). Score 56 of 100, In line with trend. Revenue growth was above the company's own trend; EBITDA and profit growth were in line with it. EBITDA margin rose 13 bps year on year. Share price after the results: −7.7% in 28 days (Nifty 500: +1.3%).
  • Q1 FY26: Revenue ₹348 cr (+21% year on year), EBITDA ₹78.0 cr (+22% year on year), PAT ₹44.0 cr (−2% year on year), EBITDA margin 22.4% (+11 bps). Score 54 of 100, In line with trend. Revenue growth was above the company's own trend; EBITDA and profit growth were below it. EBITDA margin rose 11 bps year on year. Revenue rose ₹61.0 cr on a year ago, more than the ₹44.0 cr it added the year before. Share price after the results: −1.8% in 28 days (Nifty 500: −0.9%).
  • Q4 FY25: Revenue ₹327 cr (+13% year on year), EBITDA ₹79.0 cr (+27% year on year), PAT ₹45.0 cr (0% year on year), EBITDA margin 24.2% (+278 bps). Score 58 of 100, In line with trend. EBITDA margin rose 278 bps year on year. Not enough history for a trend yet: scored on growth alone. Profit fell 15% from last quarter. Share price after the results: +3.1% in 28 days (Nifty 500: +6.9%).
  • Q3 FY25: Revenue ₹321 cr (+18% year on year), EBITDA ₹76.0 cr (+23% year on year), PAT ₹53.0 cr (+20% year on year), EBITDA margin 23.7% (+97 bps). Score 65 of 100, In line with trend. EBITDA margin rose 97 bps year on year. Not enough history for a trend yet: scored on growth alone.
  • Q2 FY25: Revenue ₹323 cr (+23% year on year), EBITDA ₹75.0 cr (+23% year on year), PAT ₹52.0 cr (+53% year on year), EBITDA margin 23.2% (+3 bps). Score 74 of 100, Above trend. EBITDA margin was flat year on year. Not enough history for a trend yet: scored on growth alone.

Past price moves after results do not indicate future moves. Not a recommendation.

Jupiter Life Line Hospitals Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.